Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients Homozygous for the F508del Mutation? A Randomized, Double Blind, Placebo-controlled Study.
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Cumulated changes in response to Chloride-free solution and isoproterenol (reflecting chloride transport)
研究概览
简要总结
The purpose of this study is to investigate the effect of a nasal instillation of Vardenafil on nasal potential difference in cystic fibrosis patients homozygous for the F508del mutation
详细描述
CFTR protein has been shown to be an ohmic, small conductance channel regulated by cAMP intracellular levels that are balanced by degradation through cyclic nucleotide phosphodiesterases (PDE). Several families of PDEs with varying selectivities for cAMP and/or cGMP have been identified.PDE5 is highly specific for cGMP and is involved in the regulation of the intracellular concentration of cGMP in various tissues. Recently, it has been shown, in a preclinical model of transgenic mice, that pharmacological doses of sildenafil and vardenafil, two clinically approved PDE5 inhibitors, stimulate chloride transport activity of the mutant F508del-protein (Lubamba et al, 2008); this parameter has been assessed by means of the nasal potential difference (NPD). An increasing effect of sildenafil on the expression of F508del-CFTR protein (Dormer et al,2005) was originally reported in nasal epithelial cells harvested from patients with cystic fibrosis and cultured on impermeable supports, a configuration that allows interaction of drugs with the apical side of epithelia.
This study aims at investigating the effect of a single local administration of vardenafil on NPD measurements in CF patients homozygous for the F508del mutation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 14 Years 至 —(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cystic fibrosis patients homozygous for the F508del mutation as confirmed by a genetic test
- •Aged 14 years and older
- •Male and female
- •FEV1 >50% of predicted normal
排除标准
- •Acute respiratory tract infection or pulmonary exacerbation requiring antibiotic intervention within 2 weeks of visit 1
- •Any condition prohibiting the correct measurement of the NPD
- •Active or passive smoking
- •Planned treatment or treatment with another investigational drug or therapy within 1 month prior to randomisation
研究组 & 干预措施
Vardenafil
nasal instillation of Vardenafil ( visit 2 or 3)
干预措施: Vardenafil (Drug)
Placebo
Nasal instillation of placebo (visit 3 or 2)
干预措施: Placebo (Drug)
结局指标
主要结局
Cumulated changes in response to Chloride-free solution and isoproterenol (reflecting chloride transport)
时间窗: Change from baseline (visit 1) and placebo to Vardenafil instillation
次要结局
- Change in basal voltage value and in amiloride response (reflecting sodium transport)(Change from baseline (visit1) and placebo to Vardenafil instillation)
